[ad_1]
An Alaskan health worker suffered a severe allergic reaction after receiving the vaccine against COVID-19 by Pfizer-BioNTech and is now hospitalized, but stable, according to a report released Wednesday.
The newspaper The New York Times reported that the person received their dose on Tuesday, while Pfizer confirmed that it was working with local authorities to investigate the incident.
“We do not yet have all the details of the Alaska report on possible severe allergic reactions, but we are actively working with local health authorities to assess.” the case, said a Pfizer spokesman.
Can read
The volunteers who showed up for the Pfizer clinical trial, which numbered 44,000 people, were excluded if they had a history of allergic reactions to vaccines or components of the immunizer against COVID-19.
” We will closely monitor all reports suggesting serious allergic reactions after vaccination and update the label text if necessary ”he added.
Overall, the trial found no serious safety concerns, but regulators and the company continue to monitor adverse cases after vaccination.
Advertising
Read also
Two healthcare workers in Britain had similar allergic reactions, prompting the European nation’s government recommend to the population to avoid receiving the vaccine if they had a history of severe allergies.
The United States’ food and drug regulator, the FDA, issued an emergency approval for the immunizer with the caveat that people who have experienced allergies to the ingredients within the vaccine should avoid it.
Precisely, the FDA published this Wednesday on its Twitter account that ”is aware of information about an anaphylactic reaction in a person who received the covid-19 vaccine ”.
It may interest you
” The agency will continue to work with the CDC (Centers for Disease Prevention) and Pfizer to better understand what happened. ”, he said.
The US began this week to apply this vaccine to about three million people and hopes to reach to a total of 20 million people this month if another immunizer is approved, the one developed by the American laboratory Moderna.
